United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

Posted by Stanley Muller on Nov 2nd, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $600.09, for a total transaction of $5,700,855.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $194,694,999.87. The trade was a 2.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

United Therapeutics Trading Down 0.4%

NASDAQ:UTHR traded down $2.59 during midday trading on Monday, reaching $596.13. The company had a trading volume of 402,365 shares, compared to its average volume of 555,103. The firm has a market capitalization of $25.57 billion, a price-to-earnings ratio of 21.33, a PEG ratio of 4.33 and a beta of 0.49. The stock’s fifty day simple moving average is $527.10 and its 200-day simple moving average is $530.54. United Therapeutics Corporation has a 12-month low of $430.02 and a 12-month high of $609.99.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter last year, the company earned $6.41 earnings per share. The firm’s revenue was down 1.9% compared to the same quarter last year. As a group, sell-side analysts expect that United Therapeutics Corporation will post 26.09 EPS for the current year.

United Therapeutics announced that its Board of Directors has approved a share buyback plan on Thursday, October 22nd that permits the company to buy back $2 billion in shares. This repurchase authorization permits the biotechnology company to reacquire up to 8.3% of its stock through open market purchases. Share repurchase plans are often an indication that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. The Goldman Sachs Group reaffirmed a “sell” rating and set a $368.00 price objective on shares of United Therapeutics in a research report on Thursday, October 15th. Bank of America cut their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Jefferies Financial Group reaffirmed a “buy” rating and set a $728.00 price target on shares of United Therapeutics in a report on Wednesday, October 14th. Morgan Stanley increased their price objective on United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a report on Wednesday, October 7th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $850.00 target price on shares of United Therapeutics in a research report on Monday, October 26th. Twelve investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $667.07.

Get Our Latest Stock Analysis on UTHR

Institutional Investors Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Arjuna Capital lifted its holdings in shares of United Therapeutics by 2.8% in the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after purchasing an additional 18 shares during the last quarter. Sage Rhino Capital LLC grew its stake in United Therapeutics by 5.1% during the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after buying an additional 23 shares during the last quarter. Bryn Mawr Trust Advisors LLC grew its stake in United Therapeutics by 5.4% during the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after buying an additional 24 shares during the last quarter. Meeder Advisory Services Inc. grew its stake in United Therapeutics by 4.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock worth $392,000 after buying an additional 26 shares during the last quarter. Finally, Kera Capital Partners Inc. increased its position in United Therapeutics by 6.1% during the first quarter. Kera Capital Partners Inc. now owns 471 shares of the biotechnology company’s stock worth $279,000 after buying an additional 27 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.